                                                                                                                                   I




                                  113TH CONGRESS
                                     1ST SESSION                          H. R. 928
                                        To amend title XVIII of the Social Security Act to deliver a meaningful
                                        benefit and lower prescription drug prices under the Medicare Program.




                                                IN THE HOUSE OF REPRESENTATIVES
                                                              FEBRUARY 28, 2013
                                  Ms. SCHAKOWSKY (for herself, Mr. FARR, Ms. LEE of California, Mr. GEORGE
                                      MILLER of California, and Ms. PINGREE of Maine) introduced the fol-
                                      lowing bill; which was referred to the Committee on Energy and Com-
                                      merce, and in addition to the Committee on Ways and Means, for a pe-
                                      riod to be subsequently determined by the Speaker, in each case for con-
                                      sideration of such provisions as fall within the jurisdiction of the com-
                                      mittee concerned




                                                                            A BILL
                                  To amend title XVIII of the Social Security Act to deliver
                                     a meaningful benefit and lower prescription drug prices
                                     under the Medicare Program.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,
                                    3     SECTION 1. SHORT TITLE.
                                    4              This Act may be cited as the ‘‘Medicare Prescription
                                    5 Drug Savings and Choice Act of 2013’’.





                                    1     SEC. 2. ESTABLISHMENT OF MEDICARE OPERATED PRE-    2
                                    2                             SCRIPTION DRUG PLAN OPTION.

                                    3              (a) IN GENERAL.—Subpart 2 of part D of title XVIII
                                    4 of the Social Security Act is amended by inserting after
                                    5 section 1860D–11 (42 U.S.C. 1395w–111) the following
                                    6 new section:
                                    7            ‘‘MEDICARE             OPERATED PRESCRIPTION DRUG PLAN
                                    8                                                   OPTION
                                    9              ‘‘SEC. 1860D–11A. (a) IN GENERAL.—Notwith-
                                  10 standing any other provision of this part, for each year
                                  11 (beginning with 2012), in addition to any plans offered
                                  12 under section 1860D–11, the Secretary shall offer one or
                                  13 more Medicare operated prescription drug plans (as de-
                                  14 fined in subsection (c)) with a service area that consists
                                  15 of the entire United States and shall enter into negotia-
                                  16 tions in accordance with subsection (b) with pharma-
                                  17 ceutical manufacturers to reduce the purchase cost of cov-
                                  18 ered part D drugs for eligible part D individuals who en-
                                  19 roll in such a plan.
                                  20               ‘‘(b)          NEGOTIATIONS.—Notwithstanding                                    section
                                  21 1860D–11(i), for purposes of offering a Medicare operated
                                  22 prescription drug plan under this section, the Secretary
                                  23 shall negotiate with pharmaceutical manufacturers with
                                  24 respect to the purchase price of covered part D drugs in




                                  25 a Medicare operated prescription drug plan and shall en-
                                  26 courage the use of more affordable therapeutic equivalents
                                              •HR 928 IH

                                                                                             3
                                    1 to the extent such practices do not override medical neces-
                                    2 sity as determined by the prescribing physician. To the
                                    3 extent practicable and consistent with the previous sen-
                                    4 tence, the Secretary shall implement strategies similar to
                                    5 those used by other Federal purchasers of prescription
                                    6 drugs, and other strategies, including the use of a for-
                                    7 mulary and formulary incentives in subsection (e), to re-
                                    8 duce the purchase cost of covered part D drugs.
                                    9              ‘‘(c) MEDICARE OPERATED PRESCRIPTION DRUG
                                  10 PLAN DEFINED.—For purposes of this part, the term
                                  11 ‘Medicare operated prescription drug plan’ means a pre-
                                  12 scription drug plan that offers qualified prescription drug
                                  13 coverage and access to negotiated prices described in sec-
                                  14 tion 1860D–2(a)(1)(A). Such a plan may offer supple-
                                  15 mental prescription drug coverage in the same manner as
                                  16 other qualified prescription drug coverage offered by other
                                  17 prescription drug plans.
                                  18               ‘‘(d) MONTHLY BENEFICIARY PREMIUM.—
                                  19                         ‘‘(1) QUALIFIED                     PRESCRIPTION                  DRUG   COV-
                                  20               ERAGE.—The                     monthly beneficiary premium for
                                  21               qualified prescription drug coverage and access to
                                  22               negotiated prices described in section 1860D–
                                  23               2(a)(1)(A) to be charged under a Medicare operated




                                  24               prescription drug plan shall be uniform nationally.
                                  25               Such premium for months in 2014 and each suc-


                                              •HR 928 IH

                                                                                             4
                                    1              ceeding year shall be based on the average monthly
                                    2              per capita actuarial cost of offering the Medicare op-
                                    3              erated prescription drug plan for the year involved,
                                    4              including administrative expenses.
                                    5                        ‘‘(2) SUPPLEMENTAL                      PRESCRIPTION DRUG COV-
                                    6              ERAGE.—Insofar                    as a Medicare operated prescrip-
                                    7              tion drug plan offers supplemental prescription drug
                                    8              coverage, the Secretary may adjust the amount of
                                    9              the premium charged under paragraph (1).
                                  10               ‘‘(e) USE OF A FORMULARY AND FORMULARY INCEN-
                                  11      TIVES.—

                                  12                         ‘‘(1) IN       GENERAL.—With                      respect to the oper-
                                  13               ation of a Medicare operated prescription drug plan,
                                  14               the Secretary shall establish and apply a formulary
                                  15               (and may include formulary incentives described in
                                  16               paragraph (2)(C)(ii)) in accordance with this sub-
                                  17               section in order to—
                                  18                                  ‘‘(A) increase patient safety;
                                  19                                  ‘‘(B) increase appropriate use and reduce
                                  20                         inappropriate use of drugs; and
                                  21                                  ‘‘(C) reward value.
                                  22                         ‘‘(2) DEVELOPMENT                     OF INITIAL FORMULARY.—

                                  23                                  ‘‘(A) IN         GENERAL.—In                   selecting covered




                                  24                         part D drugs for inclusion in a formulary, the
                                              •HR 928 IH

                                                                                             5
                                    1                        Secretary shall consider clinical benefit and
                                    2                        price.
                                    3                                 ‘‘(B) ROLE             OF AHRQ.—The                   Director of the
                                    4                        Agency for Healthcare Research and Quality
                                    5                        shall be responsible for assessing the clinical
                                    6                        benefit of covered part D drugs and making
                                    7                        recommendations to the Secretary regarding
                                    8                        which drugs should be included in the for-
                                    9                        mulary. In conducting such assessments and
                                  10                         making such recommendations, the Director
                                  11                         shall—
                                  12                                         ‘‘(i) consider safety concerns including
                                  13                                  those identified by the Federal Food and
                                  14                                  Drug Administration;
                                  15                                         ‘‘(ii) use available data and evalua-
                                  16                                  tions, with priority given to randomized
                                  17                                  controlled trials, to examine clinical effec-
                                  18                                  tiveness, comparative effectiveness, safety,
                                  19                                  and enhanced compliance with a drug regi-
                                  20                                  men;
                                  21                                         ‘‘(iii) use the same classes of drugs
                                  22                                  developed by United States Pharmacopeia
                                  23                                  for this part;





                                  24                                         ‘‘(iv) consider evaluations made by—




                                              •HR 928 IH

                                                                                             6
                                    1                                                  ‘‘(I) the Director under section
                                    2                                        1013 of Medicare Prescription Drug,
                                    3                                        Improvement, and Modernization Act
                                    4                                        of 2003;
                                    5                                                  ‘‘(II) other Federal entities, such
                                    6                                        as the Secretary of Veterans Affairs;
                                    7                                        and
                                    8                                                  ‘‘(III) other private and public
                                    9                                        entities, such as the Drug Effective-
                                  10                                         ness Review Project and Medicaid
                                  11                                         programs; and
                                  12                                         ‘‘(v) recommend to the Secretary—
                                  13                                                   ‘‘(I) those drugs in a class that
                                  14                                         provide a greater clinical benefit, in-
                                  15                                         cluding fewer safety concerns or less
                                  16                                         risk of side-effects, than another drug
                                  17                                         in the same class that should be in-
                                  18                                         cluded in the formulary;
                                  19                                                   ‘‘(II) those drugs in a class that
                                  20                                         provide less clinical benefit, including
                                  21                                         greater safety concerns or a greater
                                  22                                         risk of side-effects, than another drug
                                  23                                         in the same class that should be ex-




                                  24                                         cluded from the formulary; and
                                              •HR 928 IH

                                                                                             7
                                    1                                                  ‘‘(III) drugs in a class with same
                                    2                                         or similar clinical benefit for which it
                                    3                                         would be appropriate for the Sec-
                                    4                                         retary to competitively bid (or nego-
                                    5                                         tiate) for placement on the formulary.
                                    6                                 ‘‘(C)       CONSIDERATION                      OF       AHRQ      REC-
                                    7                        OMMENDATIONS.—
                                    8                                         ‘‘(i) IN           GENERAL.—The                      Secretary,
                                    9                                 after taking into consideration the rec-
                                  10                                  ommendations under subparagraph (B)(v),
                                  11                                  shall establish a formulary, and formulary
                                  12                                  incentives, to encourage use of covered
                                  13                                  part D drugs that—
                                  14                                                   ‘‘(I) have a lower cost and pro-
                                  15                                          vide a greater clinical benefit than
                                  16                                          other drugs;
                                  17                                                   ‘‘(II) have a lower cost than
                                  18                                          other drugs with same or similar clin-
                                  19                                          ical benefit; and
                                  20                                                   ‘‘(III) drugs that have the same
                                  21                                          cost but provide greater clinical ben-
                                  22                                          efit than other drugs.
                                  23                                          ‘‘(ii) FORMULARY                     INCENTIVES.—The




                                  24                                  formulary incentives under clause (i) may
                                              •HR 928 IH

                                                                                             8
                                    1                                 be in the form of one or more of the fol-
                                    2                                 lowing:
                                    3                                                  ‘‘(I) Tiered copayments.
                                    4                                                  ‘‘(II) Reference pricing.
                                    5                                                  ‘‘(III) Prior authorization.
                                    6                                                  ‘‘(IV) Step therapy.
                                    7                                                  ‘‘(V) Medication therapy manage-
                                    8                                        ment.
                                    9                                                  ‘‘(VI) Generic drug substitution.
                                  10                                         ‘‘(iii) FLEXIBILITY.—In applying such
                                  11                                  formulary incentives the Secretary may de-
                                  12                                  cide not to impose any cost-sharing for a
                                  13                                  covered part D drug for which—
                                  14                                                   ‘‘(I) the elimination of cost shar-
                                  15                                         ing would be expected to increase
                                  16                                         compliance with a drug regimen; and
                                  17                                                   ‘‘(II) compliance would be ex-
                                  18                                         pected to produce savings under part
                                  19                                         A or B or both.
                                  20                         ‘‘(3) LIMITATIONS                     ON FORMULARY.—In                any
                                  21               formulary established under this subsection, the for-
                                  22               mulary may not be changed during a year, except—
                                  23                                  ‘‘(A) to add a generic version of a covered




                                  24                         part D drug that entered the market;
                                              •HR 928 IH

                                                                                             9
                                    1                                 ‘‘(B) to remove such a drug for which a
                                    2                        safety problem is found; and
                                    3                                 ‘‘(C) to add a drug that the Secretary
                                    4                        identifies as a drug which treats a condition for
                                    5                        which there has not previously been a treatment
                                    6                        option or for which a clear and significant ben-
                                    7                        efit has been demonstrated over other covered
                                    8                        part D drugs.
                                    9                        ‘‘(4) ADDING                DRUGS TO THE INITIAL FOR-
                                  10               MULARY.—
                                  11                                  ‘‘(A) USE         OF ADVISORY COMMITTEE.—The
                                  12                         Secretary shall establish and appoint an advi-
                                  13                         sory committee (in this paragraph referred to
                                  14                         as the ‘advisory committee’)—
                                  15                                         ‘‘(i) to review petitions from drug
                                  16                                  manufacturers, health care provider orga-
                                  17                                  nizations, patient groups, and other enti-
                                  18                                  ties for inclusion of a drug in, or other
                                  19                                  changes to, such formulary; and
                                  20                                         ‘‘(ii) to recommend any changes to the
                                  21                                  formulary established under this sub-
                                  22                                  section.
                                  23                                  ‘‘(B) COMPOSITION.—The advisory com-




                                  24                         mittee shall be composed of 9 members and
                                  25                         shall include representatives of physicians,


                                              •HR 928 IH

                                                                                         10
                                    1                        pharmacists, and consumers and others with ex-
                                    2                        pertise in evaluating prescription drugs. The
                                    3                        Secretary shall select members based on their
                                    4                        knowledge of pharmaceuticals and the Medicare
                                    5                        population. Members shall be deemed to be spe-
                                    6                        cial Government employees for purposes of ap-
                                    7                        plying the conflict of interest provisions under
                                    8                        section 208 of title 18, United States Code, and
                                    9                        no waiver of such provisions for such a member
                                  10                         shall be permitted.
                                  11                                  ‘‘(C) CONSULTATION.—The advisory com-
                                  12                         mittee shall consult, as necessary, with physi-
                                  13                         cians who are specialists in treating the disease
                                  14                         for which a drug is being considered.
                                  15                                  ‘‘(D) REQUEST                 FOR STUDIES.—The               advi-
                                  16                         sory committee may request the Agency for
                                  17                         Healthcare Research and Quality or an aca-
                                  18                         demic or research institution to study and make
                                  19                         a report on a petition described in subpara-
                                  20                         graph (A)(ii) in order to assess—
                                  21                                         ‘‘(i) clinical effectiveness;
                                  22                                         ‘‘(ii) comparative effectiveness;
                                  23                                         ‘‘(iii) safety; and





                                  24                                         ‘‘(iv) enhanced compliance with a
                                  25                                  drug regimen.


                                              •HR 928 IH

                                                                                         11
                                    1                                 ‘‘(E) RECOMMENDATIONS.—The advisory
                                    2                        committee shall make recommendations to the
                                    3                        Secretary regarding—
                                    4                                        ‘‘(i) whether a covered part D drug is
                                    5                                 found to provide a greater clinical benefit,
                                    6                                 including fewer safety concerns or less risk
                                    7                                 of side-effects, than another drug in the
                                    8                                 same class that is currently included in the
                                    9                                 formulary and should be included in the
                                  10                                  formulary;
                                  11                                         ‘‘(ii) whether a covered part D drug is
                                  12                                  found to provide less clinical benefit, in-
                                  13                                  cluding greater safety concerns or a great-
                                  14                                  er risk of side-effects, than another drug in
                                  15                                  the same class that is currently included in
                                  16                                  the formulary and should not be included
                                  17                                  in the formulary; and
                                  18                                         ‘‘(iii) whether a covered part D drug
                                  19                                  has the same or similar clinical benefit to
                                  20                                  a drug in the same class that is currently
                                  21                                  included in the formulary and whether the
                                  22                                  drug should be included in the formulary.
                                  23                                  ‘‘(F) LIMITATIONS                    ON REVIEW OF MANU-
                                  24                         FACTURER               PETITIONS.—The                          advisory   com-
                                  25                         mittee shall not review a petition of a drug


                                              •HR 928 IH

                                                                                         12
                                    1                        manufacturer under subparagraph (A)(ii) with
                                    2                        respect to a covered part D drug unless the pe-
                                    3                        tition is accompanied by the following:
                                    4                                         ‘‘(i) Raw data from clinical trials on
                                    5                                 the safety and effectiveness of the drug.
                                    6                                         ‘‘(ii) Any data from clinical trials con-
                                    7                                 ducted using active controls on the drug or
                                    8                                 drugs that are the current standard of
                                  109                                 care.   ‘‘(iii) Any available data on compara-
                                  11                                  tive effectiveness of the drug.
                                  12                                          ‘‘(iv) Any other information the Sec-
                                  13                                  retary requires for the advisory committee
                                  14                                  to complete its review.
                                  15                                  ‘‘(G) RESPONSE                TO RECOMMENDATIONS.—
                                  16                         The Secretary shall review the recommenda-
                                  17                         tions of the advisory committee and if the Sec-
                                  18                         retary accepts such recommendations the Sec-
                                  19                         retary shall modify the formulary established
                                  20                         under this subsection accordingly. Nothing in
                                  21                         this section shall preclude the Secretary from
                                  22                         adding to the formulary a drug for which the
                                  23                         Director of the Agency for Healthcare Research




                                  24                         and Quality or the advisory committee has not
                                  25                         made a recommendation.


                                              •HR 928 IH

                                                                                         13
                                    1                                 ‘‘(H) NOTICE                 OF       CHANGES.—The             Sec-
                                    2                        retary shall provide timely notice to bene-
                                    3                        ficiaries and health professionals about changes
                                    4                        to the formulary or formulary incentives.
                                    5              ‘‘(f) INFORMING BENEFICIARIES.—The Secretary
                                    6 shall take steps to inform beneficiaries about the avail-
                                    7 ability of a Medicare operated drug plan or plans including
                                    8 providing information in the annual handbook distributed
                                    9 to all beneficiaries and adding information to the official
                                  10 public Medicare Web site related to prescription drug cov-
                                  11 erage available through this part.
                                  12               ‘‘(g) APPLICATION                   OF      ALL OTHER REQUIREMENTS
                                  13      FOR      PRESCRIPTION DRUG PLANS.—Except as specifically
                                  14 provided in this section, any Medicare operated drug plan
                                  15 shall meet the same requirements as apply to any other
                                  16 prescription drug plan, including the requirements of sec-
                                  17 tion 1860D–4(b)(1) relating to assuring pharmacy ac-
                                  18 cess).’’.
                                  19               (b) CONFORMING AMENDMENTS.—
                                  20                         (1) Section 1860D–3(a) of the Social Security
                                  21               Act (42 U.S.C. 1395w–103(a)) is amended by add-
                                  22               ing at the end the following new paragraph:
                                  23                         ‘‘(4) AVAILABILITY                    OF THE MEDICARE OPER-
                                  24               ATED PRESCRIPTION DRUG PLAN.—A                                            Medicare op-
                                  25               erated prescription drug plan (as defined in section


                                              •HR 928 IH

                                                                                         14
                                    1              1860D–11A(c)) shall be offered nationally in accord-
                                    2              ance with section 1860D–11A.’’.
                                    3                        (2)(A) Section 1860D–3 of the Social Security
                                    4              Act (42 U.S.C. 1395w–103) is amended by adding
                                    5              at the end the following new subsection:
                                    6              ‘‘(c) PROVISIONS ONLY APPLICABLE                                                IN   2006
                                    7 THROUGH 2013.—The provisions of this section shall only
                                    8 apply with respect to 2006 through 2013.’’.
                                    9                        (B) Section 1860D–11(g) of such Act (42
                                  10               U.S.C. 1395w–111(g)) is amended by adding at the
                                  11               end the following new paragraph:
                                  12                         ‘‘(8) NO             AUTHORITY FOR FALLBACK PLANS
                                  13               AFTER 2013.—A                  fallback prescription drug plan shall
                                  14               not be available after December 31, 2013.’’.
                                  15                         (3) Section 1860D–13(c)(3) of the Social Secu-
                                  16               rity Act (42 U.S.C. 1395w–113(c)(3)) is amended—
                                  17                                  (A) in the heading, by inserting ‘‘AND
                                  18                         MEDICARE               OPERATED                PRESCRIPTION                DRUG
                                  19                         PLANS’’       after ‘‘FALLBACK                   PLANS’’;        and
                                  20                                  (B) by inserting ‘‘or a Medicare operated
                                  21                         prescription drug plan’’ after ‘‘a fallback pre-
                                  22                         scription drug plan’’.
                                  23                         (4) Section 1860D–16(b)(1) of the Social Secu-




                                  24               rity Act (42 U.S.C.1395w–116(b)(1)) is amended—
                                              •HR 928 IH

                                                                                         15
                                    1                                 (A) in subparagraph (C), by striking
                                    2                        ‘‘and’’ after the semicolon at the end;
                                    3                                 (B) in subparagraph (D), by striking the
                                    4                        period at the end and inserting ‘‘; and’’; and
                                    5                                 (C) by adding at the end the following new
                                    6                        subparagraph:
                                    7                                 ‘‘(E) payments for expenses incurred with
                                    8                        respect to the operation of Medicare operated
                                    9                        prescription drug plans under section 1860D–
                                  10                         11A.’’.
                                  11                         (5) Section 1860D–41(a) of the Social Security
                                  12               Act (42 U.S.C. 1395w–151(a)) is amended by add-
                                  13               ing at the end the following new paragraph:
                                  14                         ‘‘(19) MEDICARE                       OPERATED                 PRESCRIPTION
                                  15               DRUG PLAN.—The                     term ‘Medicare operated prescrip-
                                  16               tion drug plan’ has the meaning given such term in
                                  17               section 1860D–11A(c).’’.
                                  18      SEC. 3. IMPROVED APPEALS PROCESS UNDER THE MEDI-
                                  19                              CARE OPERATED PRESCRIPTION DRUG PLAN.
                                  20               Section 1860D–4(h) of the Social Security Act (42
                                  21 U.S.C. 1305w–104(h)) is amended by adding at the end
                                  22 the following new paragraph:
                                  23                         ‘‘(4) APPEALS               PROCESS FOR MEDICARE OPER-
                                  24               ATED PRESCRIPTION DRUG PLAN.—




                                              •HR 928 IH

                                                                                         16
                                    1                                 ‘‘(A) IN         GENERAL.—The                         Secretary shall
                                    2                        develop a well-defined process for appeals for
                                    3                        denials of benefits under this part under the
                                    4                        Medicare operated prescription drug plan. Such
                                    5                        process shall be efficient, impose minimal ad-
                                    6                        ministrative burdens, and ensure the timely
                                    7                        procurement of non-formulary drugs or exemp-
                                    8                        tion from formulary incentives when medically
                                    9                        necessary. Medical necessity shall be based on
                                  10                         professional medical judgment, the medical con-
                                  11                         dition of the beneficiary, and other medical evi-
                                  12                         dence. Such appeals process shall include—
                                  13                                         ‘‘(i) an initial review and determina-
                                  14                                  tion made by the Secretary; and
                                  15                                         ‘‘(ii) for appeals denied during the ini-
                                  16                                  tial review and determination, the option of
                                  17                                  an external review and determination by
                                  18                                  an independent entity selected by the Sec-
                                  19                                  retary.
                                  20                                  ‘‘(B) CONSULTATION                      IN DEVELOPMENT OF
                                  21                         PROCESS.—In                developing the appeals process
                                  22                         under subparagraph (A), the Secretary shall
                                  23                         consult with consumer and patient groups, as




                                  24                         well as other key stakeholders to ensure the
                                              •HR 928 IH

                                                                                         17
                                    1                        goals        described              in      subparagraph              (A)   are
                                    2                        achieved.’’.
                                              •HR 928 IH                                   Æ
